Cargando…

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY

Detalles Bibliográficos
Autores principales:	Cohen, Jonathon, Roeker, Lindsey, Cheah, Chan, Eyre, Toby, Patel, Krish, Woyach, Jennifer, Seymour, John, Wang, Michael, Wang, Yucai, Loubert, Angely, Payakachat, Nalin, Hess, Lisa, Abada, Paolo, Mato, Anthony R., Ghia, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431003/ http://dx.doi.org/10.1097/01.HS9.0000971344.34270.c5

Ejemplares similares

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
por: Jurczak, Wojciech, et al.
Publicado: (2023)

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Eyre, T. A., et al.
Publicado: (2022)

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT
por: Jurczak, Wojciech, et al.
Publicado: (2023)

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Scarfò, Lydia, et al.
Publicado: (2023)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
por: Eyre, T. A., et al.
Publicado: (2022)

A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies
por: Regnault, Antoine, et al.
Publicado: (2023)

PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
por: Jurczak, W., et al.
Publicado: (2022)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
por: Chen, Sunnia T., et al.
Publicado: (2022)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

Evaluating the impact of calibration of patient-reported outcomes measures on results from randomized clinical trials: a simulation study based on Rasch measurement theory
por: Loubert, Angély, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Fungal Planet description sheets: 1112–1181
por: Crous, P.W., et al.
Publicado: (2020)

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
por: Thompson, Philip A., et al.
Publicado: (2023)

Bruins-in-Genomics: Evaluation of the impact of a UCLA undergraduate summer program in computational biology on participating students
por: Coller, Hilary A., et al.
Publicado: (2022)

Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials
por: Loubert, Angely, et al.
Publicado: (2020)

Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance
por: Liu, Shuozi, et al.
Publicado: (2022)

11,12-Dichlorodibenzo[a,c]phenazine
por: Imeri, Arta, et al.
Publicado: (2012)

1112. Detection of Enteric Viruses in Children With Acute Gastroenteritis
por: Hamdan, Lubna, et al.
Publicado: (2018)

Health Literacy in Obstetric Patients: A Pharmacist’s Experience with The Newest Vital Sign
por: Ragland, Denise, et al.
Publicado: (2015)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies
por: Regnault, Antoine, et al.
Publicado: (2023)

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
por: Brem, Elizabeth A., et al.
Publicado: (2022)

Immune response to COVID‐19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy
por: Rankin, Katherine, et al.
Publicado: (2023)

Impact of emergency contraception status on unintended pregnancy: observational data from a women’s health practice
por: Payakachat, Nalin, et al.
Publicado: (2010)

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
por: Aslan, Burcu, et al.
Publicado: (2022)

P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS
por: Lamanna, Nicole, et al.
Publicado: (2023)

Comparison of NMR and crystal structures for the proteins TM1112 and TM1367
por: Mohanty, Biswaranjan, et al.
Publicado: (2010)

IL-13 -1112 polymorphism and periodontitis susceptibility: a meta-analysis
por: Zhang, Wenbo, et al.
Publicado: (2018)

11,12 Epoxyeicosatrienoic Acid Rescues Deteriorated Wound Healing in Diabetes
por: Sommer, Katharina, et al.
Publicado: (2021)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Chemoenzymatic synthesis of polypeptides in neat 1,1,1,2-tetrafluoroethane solvent
por: Aguirre-Díaz, Isabel S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pru2bta719393legcq05amkphf